

Tuberculosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/T8C22A77C40AEN.html>

Date: June 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: T8C22A77C40AEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Tuberculosis - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Tuberculosis Understanding

Tuberculosis: Overview

Tuberculosis (TB) is caused by bacteria (*Mycobacterium tuberculosis*) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it. People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill.

'Tuberculosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tuberculosis pipeline landscape is provided which includes the disease overview and Tuberculosis treatment guidelines. The assessment part of the report embraces, in depth Tuberculosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The therapies under development are focused on novel approaches to treat/improve Tuberculosis.

Tuberculosis Emerging Drugs Chapters

This segment of the Tuberculosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tuberculosis Emerging Drugs

Telacebec (Q203): Qurient Co

Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.

VPM1002: Serum Institute of India

VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase 3 stage of development for the treatment of Tuberculosis.

Further product details are provided in the report..

Tuberculosis: Therapeutic Assessment

This segment of the report provides insights about the different Tuberculosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tuberculosis

There are approx. 35+ key companies which are developing the therapies for Tuberculosis. The companies which have their Tuberculosis drug candidates in the most advanced stage, i.e. phase III include, Serum Institute of India.

Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tuberculosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberculosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberculosis drugs.

Tuberculosis Report Insights

- Tuberculosis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Tuberculosis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Tuberculosis drugs?

How many Tuberculosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberculosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberculosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Tuberculosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Qurient Co

Kadmon Gene Therapy Holdings

Catabasis Pharmaceuticals

Sequella

Archivel Farma

AJ Vaccines

Sanofi Pasteur

Aeras

Immune Network

Crucell

Silence Therapeutics

Biofabri

GlaxoSmithKline

NEARMEDIC

Otsuka Pharmaceutical

LegoChem Biosciences

Spero Therapeutics

Tianjin CanSino Biotechnology

AnHui Longcom Biologic Pharmacy

Shanghai Jiatan Pharmatech

GC Pharma

Key Products

Telacebec (Q203)

VPM1002

CAT 5571

Sutezolid

TBI 223

RUT Ag85B-ESAT-6-IC31

AERAS-404

AERAS-456

V-7 Immunitor

AERAS-402/Crucell Ad35

IMM 201

MTBVAC

GSK 692342

GSK 3036656

PBTZ-169

TBA 7371

OPC 167832

Delpazolid

MVA 85A

SPR 720

Ad5 Ag85A

ID 93

SQ 109

AEC / BC02

WX-081

GC 3107A

TBA-7371

TBAJ-876

TBI-223

Contents

Introduction

Executive Summary

Tuberculosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Tuberculosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Tuberculosis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Tuberculosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

VPM1002: Serum Institute of India

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Telacebec (Q203): Qurient Co

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

- Comparative Analysis

Drug name: Company name

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

- Comparative Analysis

CAT 5571: Catabasis Pharmaceuticals

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

Inactive Products

- Comparative Analysis

Tuberculosis Key Companies

Tuberculosis Key Products

Tuberculosis- Unmet Needs

Tuberculosis- Market Drivers and Barriers

Tuberculosis- Future Perspectives and Conclusion

Tuberculosis Analyst Views

Tuberculosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Tuberculosis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Tuberculosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Tuberculosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T8C22A77C40AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T8C22A77C40AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970